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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe molecules and mechanisms pertinent to the low immunogenicity of undifferentiated embryonic stem cells (ESCs) remain poorly
understood. Here, we provide evidence that milk fat globule epidermal growth factor 8 (MFG-E8) is a vital mediator in this phenomenon
and directly suppresses T cell immune responses. MFG-E8 is enriched in undifferentiated ESCs but diminished in differentiated ESCs.
Upregulation of MFG-E8 in ESCs increases the successful engraftment of both undifferentiated and differentiated ESCs across major
histocompatibility complex barriers. MFG-E8 suppresses T cell activation/proliferation and inhibits Th1, Th2, and Th17 subpopulations
while increasing regulatory T cell subsets. Neutralizing MFG-E8 substantially abrogates these effects, whereas addition of recombinant
MFG-E8 to differentiated ESCs restores immunosuppression. Furthermore, we provide the evidence that MFG-E8 suppresses T cell
activation and regulates T cell polarization by inhibiting PKCq phosphorylation through the a3/5bV integrin receptor. Our findings offer
an approach to facilitate transplantation acceptance.INTRODUCTION
Understanding the molecular mechanisms governing
transplantation acceptance is essential for successful stem
cell-based therapies. Undifferentiated embryonic stem cells
(ESCs) have been considered ‘‘immune privileged’’ tissues,
but they become much more immunogenic upon in vivo
differentiation (Robertson et al., 2007; Zhao et al., 2011).
The low immunogenicity of undifferentiated ESCs has
been associated with the low level of major histocompati-
bility complex (MHC) molecules and the absence of co-
stimulatory molecules that would promote activation of
allo-specific T cells (Boyd and Wood, 2009; Drukker et al.,
2002, 2006). However, mechanisms underlying the lack
of immunogenicity seem to be more complicated than
originally speculated. Koch et al. have demonstrated that
ESCs exert local immunosuppression through the produc-
tion of soluble anti-inflammatory cytokines (Koch et al.,
2008). We also observed that undifferentiated ESC-derived
soluble factors (i.e., the water-soluble fraction of sonicated
ESCs) modulate T cell functions (Mohib et al., 2012). How-
ever, the definedmolecules and underlyingmechanisms of
their actions have not been revealed.
Here, we report that milk fat globule epidermal growth
factor 8 (MFG-E8)/lactadherin is a key determinant. MFG-
E8, a secreted glycoprotein, was initially identified inmam-
mary gland epithelial cells. Further studies have revealed its
anti-inflammatory functions in macrophages, where it as-
sists in the phagocytosis of apoptotic cells through aVb3/Stem Cell RaVb5 integrins (Brissette et al., 2012; Jinushi et al., 2007;
Yang et al., 2011). However, molecular mechanisms perti-
nent to MFG-E8 expression in health and diseased condi-
tions remain largely unknown. In addition, the functions
of MFG-E8 on T cells and ESCs have not yet been reported.
In this study, we demonstrate that MFG-E8 is essential in
sustaining the ‘‘immune privileged’’ status of undifferenti-
ated ESCs and in facilitating the acceptance of ESC-derived
tissues across allogeneic MHC barriers and thus enabling
the suppression of T cell-mediated immune responses
through the PKCq pathway.RESULTS
Undifferentiated, but Not Differentiated, ESCs Express
High Levels of MFG-E8, and Upregulation of MFG-E8
Enables Survival and Engraftment of Undifferentiated
and Differentiated Allogeneic ESCs
To define molecules with immunomodulatory potential in
ESCs, we searched literature and proteomics databases
(Graumann et al., 2008; Sarkar et al., 2012; Segura et al.,
2005; Van Hoof et al., 2006) and selected the proteins
that were closely associated with immune regulation and
also highly expressed in and secreted by undifferentiated
ESCs while diminished upon ESC differentiation. We
found that, except for MFG-E8, other proteins originally
selected were inefficient in the inhibition of T cell function
in preliminary experiments and so were excluded fromeports j Vol. 5 j 741–752 j November 10, 2015 j ª2015 The Authors 741
(legend on next page)
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further investigation. As shown in Figures 1A and 2A, the
gene and protein expression of MFG-E8 was diminished
in a timely manner after spontaneous in vitro differentia-
tion of embryoid body (EB) (i.e., formation of cellular ag-
gregates). In addition,Mfg-e8 gene was also downregulated
after in vivo ESC differentiation (i.e., teratoma formation;
Figure 1B). To determine whetherMFG-E8 has an immuno-
regulatory function in ESCs, we transduced Mfg-e8 gene
into B6 wild-type ESCs (B6-WT, derived from C57BL/6
H-2b mice) with a lentiviral vector (B6-MFG-E8 ESCs; Fig-
ure 2A) and implanted B6 B6-WT and B6-MFG-E8 ESCs
into syngeneic C57BL/6 recipients. As expected, both B6-
WT and B6-MFG-E8 ESCs formed teratomas containing
significantly different levels of MFG-E8 proteins in the re-
cipients (Figure 2B). In both instances, teratomas displayed
the same differentiated structures representing three germ
layers and showed a similar level of the MHC class I deter-
minant H-2Kb expression 4 weeks after injections (Figures
2C, 2D, and 3B). In addition, differentiated B6-WT ESCs
showed a significant decrease in gene and protein expres-
sion of MFG-E8 in comparison to their undifferentiated
counterparts. In contrast, teratomas generated from B6-
MFG-E8 ESCs sustained a high level of MFG-E8 expression
(Figures 1B and 2B). These results suggest that the differen-
tiation capacity and MHC-I expression in B6 ESCs are not
altered after MFG-E8 overexpression.
To determine whether MFG-E8 in ESCs was capable of
facilitating graft acceptance across anMHC barrier, we sub-
cutaneously transplanted B6-MFG-E8 ESCs into allogeneic
BALB/c (H-2d) mice. In allogeneic settings, B6-WT ESCsFigure 1. Undifferentiated, but Not Differentiated, ESCs Expres
Survival and Engraftment of Undifferentiated and Differentiated
(A) Western blot analysis of MFG-E8 protein expression in undifferen
sentative of three independent experiments. Densitometry results rep
cultures with a-tubulin as a loading control. Abbreviation: ESC B6-
embryoid body; Day5 diff B6-WT, day5 differentiated B6-wild-type E
blastocysts.
(B) qPCR analysis of Mfg-e8 mRNA levels in undifferentiated B6 ESCs a
after injection into C57BL/6 mice. Data represent means ± SD of unp
(C) No detectable teratomas developed after transplantation of B6-W
generated after injection of B6-MFG-E8 ESCs into nine BALB/c mice (
(D–F) H&E staining of sections from B6-WT ESC injection sites (with
orescent staining of sections corresponding to each H&E staining show
CD8+ (red), and CD4+/Foxp3+ (red/green with image analysis results;
Nuclei were counterstained with DAPI (blue). Scale bars, 200 mm (H&
(G) Only two of eight allogeneic mice transplanted with B6-WT EBs
planted with B6-MFG-E8 EBs are engrafted with larger implants. Arrow
in Figure S1A.
(H) Histological analysis of serial sections after 15-day transplantat
nofluorescent staining of sections corresponding to each H&E staining
(red) and CD8+ (red). Nuclei were counterstained with DAPI (blue). K
staining).
See also Figure S1 for CD4+/Foxp3+ Treg results. *p < 0.05, **p < 0.0
Stem Cell Rfailed to form any detectable teratomas, whereas B6-MFG-
E8 ESCs survived and generated five teratomas in nine im-
plantations (Figure 1C). Immunofluorescent staining and
histological analysis demonstrated that allogeneic B6-WT
ESCs elicited severe graft infiltration of CD4+ and CD8+
T cells in the transplanted remnant (Figures 1D and 1E),
suggesting that allogeneic B6-WT ESCs and their deriva-
tives were destroyed by host alloimmune responses.
Conversely, allogeneic B6-MFG-E8 ESCs formed typical ter-
atomas with unnoticeable tissue necrosis but detectable
MHC-I (H-2Kb) expression (Figure 1D). Importantly, in
contrast to B6-WT controls, B6-MFG-E8 teratomas dis-
played limited numbers of infiltrating Tcells while contain-
ing a high percentage of CD4+Foxp3+ regulatory T cells
(Tregs; Figure 1F). Semiquantitative immunohistological
analyses of syngeneic and allogeneic teratomas are summa-
rized in Table S1.
To further determine whether MFG-E8 also facilitates
engraftment of in vitro differentiated allogeneic ESCs, we
derived EBs from B6-WT and B6-MFG-E8 ESCs by forma-
tion of cellular aggregates and cultured them in the absence
of leukemia inhibitory factor for 7 days. This differentia-
tion procedure has been used commonly in the field and
represents a turning point for the early development of
specialized tissues (Lumelsky et al., 2001; Mizuseki et al.,
2003; Nat et al., 2012; Van Vliet et al., 2012). The differen-
tiated EBs showed low levels of pluripotency genes
(Figure 3E) but increased levels of MHC-I (H-2Kb) prior to
transplantation under the kidney capsule of syngeneic
or allogeneic recipients (Figure 3A). As expected, alls High Levels of MFG-E8, and Upregulation of MFG-E8 Enables
Allogeneic ESCs
tiated ESCs and their differentiated derivatives. Results are repre-
resent means ± SD of cells obtained from three separate unpooled
WT, B6 ESC line derived from C57BL/6 H-2b wild-type mouse; EB,
SCs; ESC D3 cell line, D3 ESC line derived from 129S2/SvPas mouse
nd their differentiated derivatives in teratomas developing 4 weeks
ooled samples from three different mice.
T ESCs into nine allogenic BALB/c mice, and five teratomas were
p < 0.05). Scale bars, 0.5 cm in insets.
out teratoma formation) or B6-MFG-E8 ESC teratomas. Immunoflu-
s expression of MHC-I (H-2Kb, green) and infiltrations of CD4+ (red),
mean ± SD from three mice per group, three sections per mouse).
E) and 20 mm (immunofluorescent staining).
show small implants, whereas eight of nine allogeneic mice trans-
head: implants. For a comparison, the same images are shown again
ion of EBs differentiated from B6-WT and B6-MFG-E8 ESCs. Immu-
shows expression of MHC-I (H-2Kb, green) and infiltrations of CD4+
, kidney; scale bars, 200 mm (H&E) and 20 mm (immunofluorescent
1, ***p < 0.001.
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Figure 2. Teratoma Formation of B6-WT and B6-MEG-E8 ESCs in Syngeneic C57BL/6 Mice
(A) B6 wild-type ESCs (B6-WT) were transduced with a lentiviral vector encoding MFG-E8 and GFP, followed by drug selection to establish a
stable ESC line with upregulated MFG-E8 expression (B6-MFG-E8 ESCs). qPCR and western blot were performed to assess MFG-E8 expression
as indicated. b-Actin was used as a normalization control for qPCR and a-tubulin for western blot (which was quantified by densitometry
from three independent experiments).
(B) The expression levels of MFG-E8 protein in teratomas after transplantation of B6-MFG-E8 and B6-WT ESC cells into syngeneic mice.
n = 3, *p < 0.05.
(C) Both B6-WT and B6-MFG-E8 ESCs formed teratomas in syngeneic C57BL/6 mice after 4 weeks of transplantation into two flank regions
(n = 5 mice). Scale bars, 1 cm.
(D) Teratomas generated from both B6-WT and B6-MFG-E8 ESCs were composed of tissues representing three germ layers, including
ectoderm (i, ii: neural rosettes and glial tissue; iii, iv: cystic epithelium), mesoderm (v: striated muscle; vi: cartilage and osteoid island),
and endoderm (vii, viii: glandular epithelium). Scale bars, 50 mm.
Abbreviations: Diff ESC, differentiated ESCs; Macrophage, RAW macrophage line as a positive control; Myoblast, C2C12 myoblast cells as a
negative control.implanted EBs were accepted by syngeneic mice and grew
well (Figures 3F and 3G). However, in allogeneic BALB/c
recipients, the majority of B6-WT EBs failed to grow and
the implants showed severe infiltration of T cells with a
low proportion of CD4+Foxp3+ Tregs. In contrast, eight of
nine allogeneic mice transplanted with B6-MFG-E8 EBs
were engrafted, and the implants showed limited T cell744 Stem Cell Reports j Vol. 5 j 741–752 j November 10, 2015 j ª2015 Theinfiltration with a higher proportion of CD4+Foxp3+ Tregs
(Figures 1G, 1H, and S1).
It is evident that overexpression of MFG-E8 in both un-
differentiated and differentiated ESCs is sufficient to reduce
allogeneic rejection (Figure 1), despite a significant increase
in the expression of MHC-I (Figures 1 and 3) and co-stimu-
latory molecules that made differentiated ESCs moreAuthors
Figure 3. Immunogenicity of Tissues
Derived from Undifferentiated and
Differentiated B6-WT and B6-MFG-E8
ESCs in Syngeneic Recipients
(A) Boxplot of mean fluorescent intensity
of MHC-I (H-2Kb) and MHC-II (I-Ab) in un-
differentiated and differentiated (diff) B6-
WT and B6-MFG-E8 ESCs. Data represent
median ± interquartile range (P25–P75)
based on flow cytometric analyses using
three unpooled different cell passages and
cultures for each group. ***p < 0.005; ns,
not significant.
(B and C) The expression of H-2Kb (green),
CD4 (red), and CD8 (red) in tumors generated
from B6-WT and B6-MFG-E8 ESCs after im-
planted into syngeneic hosts (n = 5 mice in
eachgroup).Nucleiwere counterstainedwith
DAPI (blue). Scale bars, 10 mm (B), 200 mm
(C, H&E), and 20 mm (C, CD4 and CD8).
(D and E) EBs derived from B6-WT and B6-
MFG-E8 ESCs were differentiated for 7 days,
showing a significant decrease in pluripo-
tency genes (qPCR). Data represent mean ±
SDof at least three independent experiments.
(F and G) The above EBs were transplanted
into syngeneic mice C57BL/6 under kidney
capsules and engrafted (eight out of eight
for B6-WT and eight out of eight for B6-MFG-
E8). Histological analysis of serial sections
of syngeneic B6-WT and B6-MFG-E8 EBs
12 days after transplantation. The expres-
sion of H-2Kb (green) was detected. Scale
bars, 100 mm, top panels (H&E); 20 mm, low
panels (H-2Kb expression, green). Nuclei
were counterstained with DAPI (blue).immunogenic (Fairchild et al., 2007). Since overexpression
of MFG-E8 does not inhibit MHC-I and II expression (Fig-
ure 1 and Figure 3), the immunoregulation of MFG-E8 is
not through blocking MHC. Given that sustained MFG-
E8 levels in the grafts were inversely associated with the
presence of T cell infiltration (Figure 1; Table S1), MFG-E8
might contribute to graft acceptance by suppressing T cell
responses. Although involvements of other innate inflam-
matory cells cannot be fully excluded, a study by Swijnen-
burg et al. has suggested that innate responses can be initi-
ated by surgical procedures and are not completely specific
to ESC implants (Swijnenburg et al., 2005). Accordingly, we
focused on the direct role of MFG-E8 in T cell regulation, a
question that has not been addressed.
MFG-E8 in ESCs Suppresses T Cell Activation and
Proliferation
Based on the above in vivo observations and previous find-
ings that ESC-derived soluble factors inhibited Tcell activa-Stem Cell Rtion (Mohib et al., 2012), we wanted to make a direct
link between ESC-produced MFG-E8 and T cell activation
and proliferation. ESC-derived soluble factors suppressed
expression of activation markers (CD25, CD69, and
CD44) in both CD4+ and CD8+ effector T cells stimulated
in vitro, and neutralization of MFG-E8 with a specific
antibody markedly mitigated the suppressive effects of
ESC-derived soluble factors (Figures 4A and S2A), suggest-
ing that MFG-E8 is responsible for ESC-mediated T cell
inhibition.
To further assess the immunomodulatory functions of
MFG-E8 on T cells, we stimulated the cultured mouse
splenic T cells in the absence or presence of recombinant
mouse MFG-E8 (rmMFG-E8). Treatment with rmMFG-E8
significantly suppressed both CD4+ and CD8+ effector
T cell activation, resulting in a 2-fold decrease in CD25,
CD44, and CD69 expression (Figure 4B). Conversely, intro-
duction of MFG-E8 blocking antibody, but not an isotype
control antibody, abrogated the suppression of activationeports j Vol. 5 j 741–752 j November 10, 2015 j ª2015 The Authors 745
Figure 4. MFG-E8 in ESCs Suppresses T Cell Activation and Proliferation
Negatively selected C57BL/6 CD3+ T cells were incubated with different treatment reagents, followed by stimulation with plate-bound anti-
CD3/CD28 antibodies.
(A) After stimulation, T cells were either untreated (stimulated) or treated with vehicle control (Ct), ESC-derived soluble factors alone
(ESC-ext prepared from D3 ESCs derived from 129S2/SvPas mouse blastocysts, 0.23 mg/ml), or in combination with anti-MFG-E8 antibody
(2.5 mg/ml) for 24 hr. The cells were then stained for CD4, CD8, and activation markers CD25 and CD69 and subsequently analyzed by flow
cytometry.
(B) The surface expression of CD25, CD44, and CD69 on CD4+ and CD8+ T cells was analyzed by flow cytometry in untreated control (Ct),
stimulated control, recombinant mouse MFG-E8 (rmMFG-E8) alone, rmMFG-E8 with isotype antibodies (iso Ab), rmMFG-E8 with anti-MFG-
E8 antibody, differentiated ESC-derived soluble factors (Diff ESC-ext from D3 ESCs), or Diff ESC-ext with rmMFG-E8. The dot plots are all
from one experiment in which cells were stained for CD25 and CD69 markers, and three experiments were performed with similar results.
(legend continued on next page)
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(Figure 4B). Moreover, CD4+ and CD8+ Tcell activation was
not affected after treatment with soluble factors derived
from differentiated ESCs expressing low level of MFG-E8,
with themajority of Tcells showing upregulated activation
markers after anti-CD3/CD28 stimulation. In contrast,
reconstitution of differentiated ESC-derived soluble factors
with rmMFG-E8 restored suppression, as indicated by a
reduction of all three activation markers in T cells (Fig-
ure 4B). These results demonstrate that MFG-E8 is indeed
a key component in ESC-mediated T cell inactivation.
We further tested whether MFG-E8 was capable of sup-
pressing Tcell proliferation using a carboxyfluorescein suc-
cinimidyl ester (CFSE) dilution assay with CFSE-labeled
CD3+ Tcells. In the presence of rmMFG-E8, reduced cell di-
visions in activated T cells were observed, similar to those
treated with undifferentiated ESC-derived soluble factors
(Figure 4C). Conversely, differentiated ESC-derived soluble
factors did not inhibit T cell proliferation, whereas MFG-E8
supplementation almost fully restored the suppressive ef-
fect on T cell proliferation (Figure 4C).
Together, the aforementioned results demonstrate
that MFG-E8 is a key component in ESC-derived soluble
factors that suppresses T cell activation and proliferation,
providing the evidence that MFG-E8 produced by undiffer-
entiated ESCs is directly involved in repressing T cell im-
mune responses in addition to its conventional role in
facilitating phagocytosis of apoptotic cells. Consequently,
loss ofMFG-E8 expression following ESC differentiation re-
stores normal Tcell responses to reject allogeneic implants;
conversely, sustained MFG-E8 expression in differentiated
cells inhibits T cell proliferation and activation, promoting
graft acceptance (Figures 1 and 4).
Since cells deficient in MHC-I expression (e.g., ESCs)
could be recognized by natural killer (NK) cells, we exam-
ined whether MFG-E8 also suppresses NK cell function as
measured by interferon-g (IFN-g) production (Foley et al.,
2014). As shown in Figure S2B, IFNg production in frac-
tionated NK cells was inhibited after treatment of the cells
with ESC-derived soluble factors or rmMFG-E8. It is
possible that NK cells participate in the early recognition
of transplanted ESCs that express low MHC-I based on
‘‘missing-self’’ theory (Shifrin et al., 2014). Because differ-
entiated B6-MFG-E8 EBs expressing MHC-I (H-2Kb) prior
to transplantation are engrafted (Figure 3), it appears that
T cells play a major role in successful engraftment, with
the possible contribution of NK cells, warranting further
investigation.Histograms represent the mean fluorescent intensity (MFI) of either C
Error bars indicate mean ± SD from three independent experiments; *
(C) Proliferation assays were performed on CFSE-labeled C57BL/6 CD
pendent experiments.
See also Figure S2.
Stem Cell RMFG-E8 in ESCs Suppresses Th1, Th2, and Th17
Subpopulations while Increasing Regulatory T Cells
Our results showed that B6-MFG-E8, but not B6-WT,
implants displayed limited T cell infiltration with a high
percentage of CD4+Foxp3+ Tregs (Figures 1 and S1). We
therefore tested whether MFG-E8 in undifferentiated
ESCs modulates T cell polarization induced by stimulation
with anti-CD3/CD28 or phorbol myristate acetate (PMA).
qPCR results examining the expression of lineage-specific
transcription factors indicated a significant decrease in
expression of transcriptional factors Gata3 (Th2) and Rorgt
(Th17) in T cells after treatments with rmMFG-E8 or undif-
ferentiated ESC-derived soluble factors. Conversely, MFG-
E8 neutralization restored Gata3 and Rorgt expression
(Figure 5A). Interestingly, T-bet (Th1) gene expression was
unaffected in all treatment conditions (Figure 5A) despite
a marked decrease in gene expression of the Th1-specific
cytokine Ifng (Figure S3). In an attempt to further assess
the changes in function of each Teffector cell subset attrib-
uted to MFG-E8, T cells were intracellularly stained with
IFN-g (Th1), IL-4 (Th2), and IL-17 (Th17) antibodies.
Consistent with changes in Ifng gene expression (Fig-
ure S3), T cells treated with rmMFG-E8 exhibited a notable
decrease in IFN-g-producing effector cells (Figure 5B). Like-
wise, in accordance with downregulated Gata3 and Rorgt
gene expression, the numbers of IL-4- and IL-17-producing
T cells were significantly decreased (Figures 5C and 5D).
Neutralization of MFG-E8 effectively ameliorated the
suppressive effects of rmMFG-E8 or ESC-derived soluble
factors, restoring the numbers of IFN-g-, IL-4-, and IL-17-
producing T cells (Figures 5B–5D). These data suggest that
ESC-produced MFG-E8 inhibits the development of Th1,
Th2, and Th17 subpopulations.
Furthermore, consistent with upregulated Foxp3 and Tgfb
geneexpression(genesassociatedwith regulatoryTcells; Fig-
ures 5A and S3) and increased proportions of CD4+Foxp3+
Tregs in the allografts after transplantation of B6-MFG-E8
ESCs and EBs (Figures 1F and S1B), the CD4+CD25+Foxp3+
Treg subpopulation was markedly increased after treatment
with rmMFG-E8 (Figure 5E). Of note, the elevated Treg
subpopulation induced by ESC-derived soluble factors was
almost completely blocked following the neutralization of
MFG-E8 with an antibody (Figure 5E).
Collectively, our results provide direct evidence that
ESC-produced MFG-E8 enhances polarization of the Treg
subpopulation, suppresses Th1 function, and prevents the
development of Th2 and Th17 T cells. Previous studiesD4+ or CD8+ T cells with CD44 expression for each treatment group.
p < 0.05 (ANOVA and Tukey HSD).
3+ splenic lymphocytes. Results are representative of three inde-
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Figure 5. MFG-E8 in ESCs Suppresses Th1,
Th2, and Th17 Subsets while Enhancing
the Treg Subpopulation
(A) Gene expression of transcriptional
factors representing Th1, Th2, and Th17
(qPCR). Purified CD3+ splenic T cells were
primed with anti-CD3/CD28 for 3 days and
then treated with either D3 ESC-derived
soluble factors (D3 ESC-ext, D3 ESC line
derived from 129S2/SvPas mouse blasto-
cysts) or rmMFG-E8 in the presence of
absence of MFG-E8 blocking antibody, fol-
lowed by PMA stimulation. Expression levels
of mRNA of transcriptional factors (T-bet,
Rorgt, Gata3, and Foxp3) were determined
by qPCR. Data represent mean ± SD of
at least three independent experiments;
*p < 0.05.
(B–D) rmMFG-E8 is capable of suppressing
IFN-g, IL-4, and IL-17 production. The cells
were stained with fluorescent-labeled anti-
bodies against CD4, CD25, or CD69 for sur-
face markers and IFN-g, IL-4, and IL-17 for
intracellular cytokines, followed by flow
cytometric analysis. Histograms are shown
as mean ± SD of the absolute number of
cells expressing each cytokine from three
independent experiments (*p < 0.05, **p <
0.01, ***p < 0.005).
(E) Expression of FOXP3. T cells treated and
stimulated as described above were stained
for CD4 and CD25 surface markers and then
analyzed for intracellular FOXP3 expression
by flow cytometry to assess the Treg sub-
population. The dot plots are all from one
experiment, and three experiments were
performed with similar results.
See also Figure S3.have shown that increased Treg infiltration in tumor tissues
was associated with elevated macrophage MFG-E8 expres-
sion (Jinushi et al., 2009) and development of autoimmu-
nity was correlated with downregulated MFG-E8 levels
(Peng and Elkon, 2011; Yamaguchi et al., 2008). Our study
provides a direct link between MFG-E8 and Th1, Th2,
Th17, and Treg Tcells, demonstrating that undifferentiated
ESCs are capable of skewing immune response toward an
anti-inflammatory or immune tolerant status via MFG-E8.
MFG-E8 in Undifferentiated ESCs Suppresses T Cell
Activation via Inhibition of PKCq Phosphorylation
Given an indispensable role of PKCq in T cell responses
(Healy et al., 2006) and our previous observation that748 Stem Cell Reports j Vol. 5 j 741–752 j November 10, 2015 j ª2015 TheESC-derived soluble factors inhibit PKCq phosphorylation
(Mohib et al., 2012), we speculated that MFG-E8 might
modulate T cells through PKCq. Indeed, both undifferenti-
ated ESC-derived soluble factors and rmMFG-E8 signifi-
cantly suppressed PKCq phosphorylation of activated
Tcells, and anti-MFG-E8 antibody abrogated the inhibitory
effects (Figures 6A and 6B). Additionally, differentiated
ESC- or myoblast C2C12-derived soluble factors contain-
ing little MFG-E8 did not significantly affect PKCq phos-
phorylation in T cells. Conversely, supplement of differen-
tiated ESC-derived soluble factors with rmMFG-E8 restored
inhibition (Figure 6C).
It is known that T cells selectively upregulate integrin
aVb3/aVb5 on their surface when encountering a specificAuthors
Figure 6. MFG-E8 in ESCs Inhibits PKCq
Activation
(A) Negatively selected C57BL/6 CD3+ T cells
were treated with undifferentiated ESC-
derived soluble factors (ESC-ext, prepared
from D3 ESCs derived from 129S2/SvPas
mouse blastocysts) alone or in combination
with either control isotype antibody or anti-
MFG-E8 antibody, and stimulated with anti-
CD3/CD28 antibodies. For western blot anal-
ysis, cell lysates were probed with antibodies
to phosphorylated-PKCq (Ther538), total
PKCq, and a-tubulin (as a loading control).
(B) Cells were treated with recombinant
mouse MFG-E8 (rmMFG-E8) in the absence
or presence of control isotype antibody
or anti-MFG-E8 antibody and analyzed by
western blot.
(C) Cells were treated with soluble factors
derived from undifferentiated D3 ESCs (ESC-
ext), differentiated D3 ESCs (Diff ESC-ext),
or C2C12 myoblast cell line (C2C12 myoblast
cell-ext) alone or in combination with
rmMFG-E8 and thenanalyzedbywestern blot.
(D) The aV integrin-blocking antibody
(anti-aV Ab) was introduced to restrain the
binding of MFG-E8 to its receptor. Cell
lysates were then analyzed for levels of
PKCq phosphorylation by densitometry with
a-tubulin as a loading control. Bar graphs
represent mean ± SD from at least three
independent experiments.
See also Figure S4.PKCq activator, PMA (Huang et al., 1995; Luzina et al.,
2009; Nohara et al., 2005). We reasoned that engagement
of MFG-E8 to its integrin receptor on activated T cells
might transduce a signal via PKCq in ESC-mediated immu-
nomodulation to control the level of T cell responses.
As anticipated, western blot revealed that a blockade of
aVb3/aVb receptor activity with an anti-CD51 (anti-aV)
antibody alleviated the inhibitory effect of ESC-derived
soluble factors or rmMFG-E8 on PKCq phosphorylation
(Figure 6D).
Additionally, to further confirm that inhibition of PKCq
would suppress T cell function, we transfected purified
splenic T cells with scrambled RNA or PKCq small inter-
fering RNA (siRNA) prior to stimulation with antiCD3/
CD28 (Figure S4A). With PKCq knockdown, T cell activa-
tion was impaired with a robust decrease in CD25+/
CD69+ T cells in both CD4 and CD8 subpopulations
(Figure S4B).
Furthermore, MFG-E8 specifically abolished PMA-
induced PKCq activation (Figure S4C). Since PMA is a
well-known molecule capable of upregulating PKCq activ-Stem Cell Rity, but not PKC-a, b, d, ε, and d82 (Isakov and Altman,
1987; Touraine et al., 1977; Tsutsumi et al., 1993), PKCq
is a key player involved in MFG-E8-mediated T cell regula-
tion. A role for PKCq in mouse cardiac rejection has been
reported. PKCq knockout mice exhibit an impaired alloim-
mune response and are susceptible to tolerance induction.
While a subtherapeutic dose of anti-CD154 antibody
or CTLA4-Ig failed to delay cardiac allograft rejection in
wild-type mice, it could prevent cardiac allograft rejection
in PKCq knockout mice (Manicassamy et al., 2008; Wang
et al., 2009). In this report, we made a connection between
MFG-E8, PKCq, and immune acceptance of differentiated
ESC implants.DISCUSSION
Molecules and mechanisms pertinent to the low
immunogenicity of undifferentiated ESCs remain poorly
understood. In this study, we demonstrated that MFG-E8
is enriched in undifferentiated but diminished ineports j Vol. 5 j 741–752 j November 10, 2015 j ª2015 The Authors 749
differentiated ESCs (Figures 1 and 2); upregulation ofMFG-
E8 promotes successful engraftment of non-self ESCs and
their derivatives across the MHC barrier (Figures 1, 2, 3,
and S1; Table S1).
Apparently,MFG-E8 is a key determinant in ESC-induced
T cell suppression in a PKCq-dependent manner. By sup-
pressing PKCq phosphorylation (Figures 6 and S4), ESC-
produced MFG-E8 inhibits Th1/Th2/Th17 subpopulations
while increasing regulatory T cells (Figures 4, 5, and S1–S3).
A study regarding MFG-E8-mediated tissue regeneration
has shown that MFG-E8 transduced its downstream
signaling for mucosal healing by activating intracellular
PKCε in epithelial cells (Bu et al., 2007). Given the premise
of similar structures shared between PKCq and PKCε (Mel-
lor and Parker, 1998), our findings regarding an MFG-E8
mechanistic function on PKCq in T cells suggest diversified
modes of MFG-E8 signaling in different cell types.
Our observations that MFG-E8 did not affect T-bet gene
expression while suppressing Th1 function (i.e., IFN-g pro-
duction) seem conflicting, which might pertain uniquely
to PKCq. Studies have illustrated that synergistic inhibition
of two pathways instead of PKCq alone is crucial for com-
plete suppression of Th1 differentiation (Lee et al., 2010;
Smeets et al., 2012). The requirement of collaborative path-
ways for fully controlling Th1 differentiation may provide
one possible explanation regarding our T-bet and IFN-g re-
sults (Ma et al., 2012; Marsland and Kopf, 2008; Marsland
et al., 2005).
In summary, we elucidated an immunomodulatory
mechanism by which ESCs downregulate effector T cells
while upregulating Tregs viaMFG-E8. Importantly, sustain-
ing a high level of MFG-E8 expression in differentiated
ESCs overcomes T cell-mediated immune rejection and fa-
cilitates transplant acceptance. This work provides insights
into a potential approach for stem cell-based therapies and
autoimmune diseases.EXPERIMENTAL PROCEDURES
Cell Lines, Animals, and Reagents
Mouse ESC lines C57BL/6 (B6) and D3 (derived from 129S2/SvPas
mouse blastocysts) were obtained from ATCC. Jurkat T cells were
maintained in RPMI supplemented with 10% fetal bovine serum.
C57BL/6 (H-2b) and BALB/c (H-2d) mice (8–12 weeks old) were
purchased from Charles River Laboratories and maintained at
the University of Ottawa according to the Canadian Council on
Animal Care guidelines under the protocol approved by the
Animal Use Subcommittee (permit BMI-2025). Recombinant
mouse MFG-E8 (rmMFG-E8) was purchased from R&D Systems,
and MFG-E8 antibody was prepared as described previously
(Jinushi et al., 2009). Other antibodies used were described below
or in Supplemental Experimental Procedures. See Supplemental
Experimental Procedures for detailed procedures.750 Stem Cell Reports j Vol. 5 j 741–752 j November 10, 2015 j ª2015 TheTeratoma Formation, Transplantation of EBs under
Kidney Capsules, and Histological and
Immunofluorescent Analyses
B6-WT and B6-MFG-E8 ESCs were harvested, and one to three
million cells were injected subcutaneously into the flank region
of syngeneic C57BL/6 (n = 10) or allogeneic BALB/c (n = 18)
mice to generate teratomas. Differentiated EBs were transplanted
under the kidney capsules (syngeneic transplantation: n = 16; allo-
geneic transplantation: n = 17). Frozen tumor sections were evalu-
ated after H&E staining or immunostaining. All of the specimens
were coded so that the measurements were performed blindly
for final analysis. See Supplemental Experimental Procedures for
more details.
Lentiviral Production, MFG-E8 Transduction, and
Characterization of B6-MFG-E8 ESC
293 T cells were transfected with MFG-E8 lentiviral vector encod-
ing full-length MFG-E8 and a GFP marker (Addgene plasmid
#46847), and two packing plasmids psPAX2 and pMD2.G
(Addgene plasmids 12259 and 12260) using Lipofectamine 2000
(Invitrogen). Lentivirus was harvested and concentrated using
Lenti-X concentrator (Clontech) according to the manufacturer’s
instruction. B6 wild-type (B6-WT) ESCs were infected with lenti-
virus in the presence of 10 mg/ml polybrene (Sigma). Puromycin
selection (2 mg/ml) started 48 hr after lentiviral transduction for
2 weeks with daily medium change. After establishing a stable
cell line with upregulatedMFG-E8, B6-MFG-E8 ESCs were cultured
in ESC growthmedium containing 1 mg/ml of puromycin. See Sup-
plemental Experimental Procedures for more details.
ESC Differentiation
ESCs were differentiated by formation of EBs and removal of LIF.
See Supplemental Experimental Procedures for more details.
Preparation of ESC- and Other Cell-Derived Soluble
Factors, qPCR, and Western Blot
This experimental method has been described previously (Mohib
et al., 2010). See Supplemental Experimental Procedures for more
information.
Fractionation of Mouse Splenic CD3+ T Cells and
NK Cells
Mouse spleens were removed aseptically and homogenized gently
and lysed using ACK red blood cell lysis buffer (Cedarlane Labora-
tories, catalog no. A1049201). After two washes, splenocytes were
re-suspended, and CD3+ T cells (>92% purity) or NK cells (>90%
purity) were fractionated by negative selection using a magnetic
labeling kit according to manufacturer instructions (STEMCELL
Technologies, catalog no. 19851). See Supplemental Experimental
Procedures for more information.
Flow Cytometry and Intracellular Staining
Fractionated CD3+ T cells were treated with different reagents as
described in Results, followed by stimulation with plate-coated
anti-CD3 and anti-CD28 (eBioscience, catalog no. 16-0031-85
and 16-0281-85) for 48 hr. Cells were then stained with antibodiesAuthors
against CD4, CD8, and surface activation markers (CD25, CD44,
and CD69) (eBioscience, catalog no. 15-0041-82, 11-0081-81, 48-
0253-82, 25-0691-81, and 47-0441-82, respectively). Appropriate
fluorochrome-conjugated isotype matched antibodies were used
as negative controls. Analysis was carried out in a BeckmanCoulter
Cyan cytometer, and data were analyzed using Kaluza. See Supple-
mental Experimental Procedures for detailed procedures.Statistical Analysis
Results are expressed as mean ± SD. Statistical significance was
determined using a Student’s t test, ANOVA and Tukey HSD or
chi-square test wherever applicable. Results were analyzed using
R studio, and considered significant with a p value < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experi-
mental Procedures, four figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.09.005.
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